| Literature DB >> 26451160 |
Yu-Hong Wang1, Xu-Hui Yu2, Shan-Shun Luo1, Hui Han1.
Abstract
BACKGROUND: Ageing brings about the gradual deterioration of the immune system, also known as immunosenescence. The role of non-coding circular RNA in immunosenescence is under studied. Using circular RNA microarray data, we assembled Comparison groups (C1, C2, C3 and C4) that allowed us to compare the circular RNA expression profiles between CD28(+)CD8(+) T cells and CD28(-)CD8(+) T cells isolated from healthy elderly or adult control subjects. Using a step-wise biomathematical strategy, the differentially-expressed circRNAs were identified in C1 (CD28(+)CD8(+) vs CD28(-)CD8(+)T cells in the elderly) and C4 (CD28(-)CD8(+)T cells in the elderly vs in the adult), and the commonly-expressed circRNA species from these profiles were optimized as immunosenescence biomarkers.Entities:
Keywords: Ageing; Biomathematics; CD28; Circular RNA; Microarray; T cell
Year: 2015 PMID: 26451160 PMCID: PMC4597608 DOI: 10.1186/s12979-015-0042-z
Source DB: PubMed Journal: Immun Ageing ISSN: 1742-4933 Impact factor: 6.400
The clinical characteristics of the subjects with CMV seropositivity
| Category | Elderly group | Adult group | ||
|---|---|---|---|---|
| Old-old | Middle-old | Adult-old | ||
| Number | 6 | 7 | 8 | 8 |
| Age | 90.5 ± 2.4 | 79.6 ± 2.5 | 69.3 ± 3.1 | 32.0 ± 4.6 |
| Gender (male vs female) | 3vs3 | 4vs3 | 4vs4 | 4vs4 |
| Number of chronic diseasesa | 3.4 | 3.0 | 2.9 | 0 |
| Number of daily medications(NNTs)b | 5.6 | 5.3 | 5.1 | 0 |
| Numbers of white blood cell(109 L−1) | 7.14 ± 3.67 | 7.09 ± 3.56 | 7.20 ± 2.98 | 7.98 ± 3.52 |
| Numbers of PBMC(109 L−1) | 0.44 ± 0.25 | 0.43 ± 0.26 | 0.44 ± 0.24 | 0.48 ± 0.21 |
| Numbers of CD8(+)(109 L−1) | 0.26 ± 0.14 | 0.23 ± 0.12 | 0.25 ± 0.15 | 0.24 ± 0.11 |
| Percentage ratio of CD28(+)/CD28(-) | 43.4 ± 22.1/56.6 ± 33.5 | 49.1 ± 26.5/57.1 ± 37.8 | 46.9 ± 22.1/53.1 ± 39.0 | 55.1 ± 29.2/42.6 ± 29.3 |
| C-reactive Protein(mg L−1) | 6.39 ± 2.86 | 6.26 ± 3.02 | 6.41 ± 3.27 | 5.22 ± 1.45 |
aNumber of chronic disease (multimorbidity) was calculated using 10 age-related/chronic diseases including sustained/primary hypertension, primary hyperlipidemia, type 2 diabetes, coronary atherosclerotic heart disease, chronic atrial fibrillation, preclinical valvular disease, preclinical chronic obstructive pulmonary disease, subclinical chronic liver disease, subclinical chronic renal disease, subclinical thyroid disease and long-term(subclinical > 5 years) tumor survivor
bNumber of daily medications were calculated by the number of drugs necessary to treat (NNTs). It was calculatedusing15 categories of pharmaceutical administration,including:5 oral antihypertensive drugs (angiotensin receptor blockers, angiotensin-converting enzyme inhibitors, calcium channel blockers, beta-receptor blockers, and hydrochlorothiazide); 4 oral hypoglycemic drugs (sulfonylureas, metformin, glucosidase inhibitors, and thiazolidinediones); insulin or insulin analogues; 2 lipid lowering drugs(statin and fibrate); aspirin; clopidogrel; trimetazidine; CoenzymeQ10; and isosorbidemononitrate sustained-release capsules
Fig. 1The intracellular validation of candidate circRNAs in C1 and C4. Validation of intracellular circRNA was performed using quantitative polymerase chain reaction (qPCR; in triplicate) in three randomly selected RNA samples. The level of intracellular expression of the validated circRNA was the average of these three samples. Prior to determination of the average, the normalized intracellular expression was calculated by the ratio of intracellular expression to microarray expression. Four up-regulated circRNAs (circRNA100550, circRNA100783, circRNA101328 and circRNA102592) and two down-regulated circRNAs with Top-2 Degree (circRNA103741 and circRNA101318) were validated in C1, respectively (a). Simultaneously, the same four up-regulated circRNAs and another two down-regulated circRNAs with Top-2 degree (circRNA104096 and circRNA100264) were validated in C4, respectively (b). Shown from the figure, only circRNA100783 is significantly differentially-expressed in both C1 and C4. Therefore, we supposed circRNA 1000783 might be a potential biomarker of immunosenescence
Fig. 2The biomathematical predicted circ000783-targeted circRNA-miRNA-mRNA/gene network. The circ000783-targeted circRNA-miRNA-mRNA/gene network is predicted based on sequence-pairing prediction. There are 73 miRNAs and 1930 genes being targeted in the present circ000783--miRNA-mRNA/gene network (miRNA-dependent cutoff value -0.11, mRNA-dependent cutoff value -0.38). Shown in this figure, miR-125a-5p exhibited the highest degree, followed by miR-33a-5p,miR-33b-5p,miR-580-3p,miR-499a-5p and miR-34b-3p
The microarray Fold Change of the candidate circRNAs that were step-wise selected
| circRNA | Degree | C1:Q1 vs Q2 | C4:Q2 vs Q4 |
|
|
|---|---|---|---|---|---|
| Up-regulated circRNAs | Fold Change | ||||
| hsa_circRNA_100550a | 12 |
|
|
| |
| hsa_circRNA_001259 | 10 | 2.9541118 |
| ||
| hsa_circRNA_101635 | 10 | 2.6649119 |
| ||
| hsa_circRNA_102592 | 10 | 2.1983682 |
| ||
| hsa_circRNA_100315 | 10 | 3.8537081 |
| ||
| hsa_circRNA_101358 | 9 | 5.5122991 |
|
| |
| hsa_circRNA_101384 | 9 | 10.8204701 |
|
| |
| hsa_circRNA_102592a | 9 |
|
|
| |
| hsa_circRNA_400075 | 9 | 6.9227289 |
|
| |
| hsa_circRNA_104981 | 9 | 4.8466812 | |||
| hsa_circRNA_100783a | 9 |
|
|
| |
| hsa_circRNA_101328a | 9 |
|
|
| |
| Down-regulated circRNAs | Fold Change | ||||
| hsa_circRNA_100988 | 15 | 5.6605839 |
|
| |
| hsa_circRNA_100989 | 12 |
|
| ||
| hsa_circRNA_103801 | 10 | 2.1387435 |
| ||
| hsa_circRNA_104646 | 10 | 2.5271826 |
| ||
| hsa_circRNA_100807 | 10 | 2.4750588 |
| ||
| hsa_circRNA_101318c | 10 | 7.3547169 |
|
| |
| hsa_circRNA_100264b | 10 | 4.3266365 |
| ||
| hsa_circRNA_103741c | 10 | 7.7727788 |
|
| |
| hsa_circRNA_103572 | 10 | 3.2713424 | |||
| hsa_circRNA_104096b | 10 | 3.2940966 |
| ||
| hsa_circRNA_104266 | 9 | 4.5747819 |
|
| |
| hsa_circRNA_103623 | 9 | 2.1655964 |
| ||
aUp-regulated overlapping circRNAs of C1 and C4 (FC underlined)
bDown-regulated circRNAs with Top-2 FC ofC1
Down-regulated circRNAs with Top-2 FC of C4
Note: C1:Q1 vs Q2 (CD28(+)CD8(+)T cells vs CD28(-)CD8(+)T cells in the elderly); C2:Q3 vs Q4 (CD28(+)CD8(+)T cells vs CD28(-)CD8(+)T cells in the adult); C3 = Q1 vs Q3 (CD28(+)CD8(+)T cells in the elderly vs the adult); C4 = Q2vsQ4 (CD28(-)CD8(+)T cells in the elderly vs the adult)
Fig. 3Schematic strategy of pooling circRNA microarray profiles. Eight microarrays are depicted by 8 green circles. After eight microarray profiles were individually acquired, three microarray profiles detecting CD28(+)CD8(+)T cells from three age-dependent elderly subgroups were pooled as Q1,and three microarray profiles detecting CD28(-)CD8(+)T cells from three age-dependent elderly subgroups were pooled as Q2. Consequently, four cross-group comparisons were performed as: Comparison1 (C1:Q1 vs Q2 indicating CD28(+)CD8(+) vs CD28(-)CD8(+) T cells in the elderly); Comparison2 (C2: Q3 vs Q4 indicating CD28(+)CD8(+) vs CD28(-)CD8(+)T cells in the adult); Comparison 3 (C3:Q1 vs Q3 indicating CD28(+)CD8(+)T cells in the elderly vs in the adult); and Comparison4 (C4: Q2 vs Q4 indicating CD28(-)CD8(+)T cells in the elderly vs in the adult)